HRP20210036T1 - Soli inhibitora pi3k i postupci za njihovo dobivanje - Google Patents
Soli inhibitora pi3k i postupci za njihovo dobivanje Download PDFInfo
- Publication number
- HRP20210036T1 HRP20210036T1 HRP20210036TT HRP20210036T HRP20210036T1 HR P20210036 T1 HRP20210036 T1 HR P20210036T1 HR P20210036T T HRP20210036T T HR P20210036TT HR P20210036 T HRP20210036 T HR P20210036T HR P20210036 T1 HRP20210036 T1 HR P20210036T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- lymphoma
- cancer
- cell lymphoma
- salt according
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims 14
- 238000000034 method Methods 0.000 title claims 7
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 11
- 208000003950 B-cell lymphoma Diseases 0.000 claims 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 7
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 6
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 6
- 206010047115 Vasculitis Diseases 0.000 claims 6
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000031814 IgA Vasculitis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000033386 Buerger disease Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000010007 Cogan syndrome Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000001102 germinal center b cell Anatomy 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 231100000855 membranous nephropathy Toxicity 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Claims (14)
1. Sol koja je sol klorovodične kiseline (R)-4-(3-((S)-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-fluorofenil)pirolidin-2-ona, koja je kristalna.
2. Sol prema zahtjevu 1 koja je u stehiometrijskom odnosu 1:1 (R)-4-(3-((S)-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-kloro-2-etoksi-6-fluorofenil)pirolidin-2-ona prema klorovodičnoj kiselini.
3. Sol prema zahtjevu 1 ili 2, naznačena sa DSC termogramom koji ima endotermni signal na 207 ± 3 °C.
4. Sol prema bilo kojem od patentnih zahtjeva 1-3 koja ima DSC termogram kao što je dolje prikazano:
[image]
5. Sol prema bilo kojem od patentnih zahtjeva 1-4 koja ima TGA termogram kao što je dolje prikazano:
[image]
6. Sol prema bilo kojem od zahtjeva 1-5 koja ima:
(a) najmanje jedan XRPD signal, u smislu 2-teta, odabran od 11.3° ± 0.2°, 16.4° ± 0.2°, 21.0° ± 0.2°, 23.0° ± 0.2°, 28.1° ± 0.2°, 31.2° 6 0.2°, i 32.8° 6 0.2°;
(b) najmanje dva XRPD signala, u smislu 2-teta, odabrana od 11.3° ± 0.2°, 16.4° ± 0.2°, 21.0° ± 0.2°, 23.0° ± 0.2°, 28.1° ± 0.2°, 31.2° ± 0.2°, i 32.8° ± 0.2°;
(c) najmanje tri XRPD signala, u smislu 2-teta, odabrana od 11.3° ± 0.2°, 16.4° ± 0.2°, 21.0° ± 0.2°, 23.0° ± 0.2°, 28.1° ± 0.2°, 31.2° ± 0.2°, i 32.8° ± 0.2°;
(d) najmanje četiri XRPD signala, u smislu 2-teta, odabrana od 11.3° ± 0.2°, 16.4° ± 0.2°, 21.0° ± 0.2°, 23.0° ± 0.2°, 28.1° ± 0.2°, 31.2° ± 0.2°, i 32.8° ± 0.2°;
(e) najmanje pet XRPD signala, u smislu 2-teta, odabrana od 11.3° ± 0.2°, 16.4° ± 0.2°, 21.0° ± 0.2°, 23.0° ± 0.2°, 28.1° ± 0.2°, 31.2° ± 0.2°, i 32.8° ± 0.2°.
7. Sol prema bilo kojem od zahtjeva 1-5 koja ima profil XRPD kao što je dolje prikazano:
[image]
8. Farmaceutski sastav koji sadrži sol prema bilo kojem od zahtjeva 1-7 i farmaceutski prihvatljivi nosač.
9. Postupak za inhibiranje aktivnosti PI3Kδ kinaze, in vitro, koji obuhvaća dovođenje u kontakt kinaze sa soli prema bilo kojem od zahtjeva 1-7.
10. Sol prema bilo kojem od zahtjeva 1 do 7, za upotrebu u liječenju bolesti kod pacijenta, pri čemu je spomenuta bolest izabrana od idiopatske trombocitopenijske purpure (ITP), autoimune hemolitične anemije, vaskulitisa, sistemskog lupusa eritematozusa, lupusa nefritisa, pemfigusa, autoimune hemolitične anemije (AIHA), membranozne nefropatije, kronične limfocitne leukemije (CLL), Ne-hodgkinovog limfoma (NHL), leukemije dlakastih stanica, limfoma Mantle stanica, Burkitovog limfoma, malog limfocinog limfoma, folikularnog limfoma, limfoplazmacitnog limfoma, limfoma ekstranodalne marginalne zone, Hodgkinovog limfoma, Waldenstromove makrogloblinemije, prolimfocitne leukemije, akutne limfoblastne leukemije, mijelofibroze, limfoma limfatičnog tkiva povezanog sa mukozom (MALT), limfoma B-stanica, mediastinalnog (timičnog) limfoma velikih B-stanica, limfomatoidne granulomatoze, limfoma marginalne zone slezene, primarnog efuzionog limfoma, intravaskularnog limfoma velikih B-stanica, leukemije plazma stanica, ekstramedularnog plazmacitoma, pritajenog mijeloma (tj. asimptomatskog mijeloma), monoklonalne gamapatije neodređenog značaja (MGUS) I limfoma B stanica;
ili je bolest idiopatska trombocitopenijska purpura (ITP) izabrana od relapsnog ITP i refraktornog ITP;
ili je bolest vaskulitis izabran od Behçetove bolesti, Coganovog sindroma, temporalni arteritis, reumatske polimijalgije (PMR), Takayasujevog arteritisa, Buergerove bolesti (thromboangiitis obliterans), vaskulitisa centralnog nervnog sistema, Kawasakijeve bolesti, poliarteritis nodoza, Churg-straussovog sindroma, vaskulitisa mješovite krioglobulinemije (esencijalnog ili induciranog virusom hepatitisa C (HCV)), Henoch-Schonleinove purpure (HSP), vaskulitisa induciranog hiperpreosetljivošću, mikroskopskog angilitisa, Wegenerove granulomatoze, i sistemskog vaskulitisa (AASV) induciranog sa anti-neutrofilnim citoplazmatskim antitijelom (ANCA);
ili je bolest ne-Hodgkinov limfom (NHL) odabran od relapsnog NHL, refraktornog NHL, i rekurentnog folikularnog NHL;
ili je bolest limfom B stanica, pri čemu spomenuti limfom B stanice je difuzni krupnostanični limfom B-stanica (DLBCL);
ili je bolest limfom B stanica, pri čemu spomenuti limfom B stanica je aktiviranim B-stanicama sličan (ABC) difuzni krupnostanični B limfom, ili difuzni krupnostanični B limfom (GCB) B stanica germinalnog centra;
ili je bolest osteoartritis, restenoza, ateroskleroza, poremećaji kostiju, artritis, dijabetska retnopatija, psorijaza, benigna hipertrofija prostate, upala, angiogeneza, pankreatitis, bolest bubrega, upalna bolest crijeva, mijastenija gravis, multipla skleroza, ili Sjögrenov sindrom;
ili je bolest reumatoidni artritis, alergija, astma, glomerulonefritis, lupus, ili upala povezana sa bilo kojim od prethodno spomenutih;
ili je bolest lupus koji je sistemski lupus eritematozus ili lupus nefritis;
ili je bolest rak grudi, rak prostate, rak debelog crijeva, rak endometrijuma, rak mozga, rak mokraćnog mjehura, rak kože, rak maternice, rak jajnika, rak pluća, rak gušterače, rak bubrega, rak želudca, ili hematološki rak;
ili je bolest hematološki rak koji je akutna mijeloblastna leukemija ili kronična mijeloidna leukemija;
ili je bolest akutna povreda pluća (ALI) ili adultni respiratorni distres sindrom (ARDS).
11. Postupak za dobivanje soli prema bilo kojem od patentnih zahtjeva 1-7, koji obuhvaća reakciju spoja Formule I:
[image]
sa klorovodičnom kiselinom da bi se oblikovala spomenuta sol.
12. Postupak prema zahtjevu 11, pri čemu spomenuta klorovodična kiselina je 1 M klorovodična kiselina u vodi.
13. Postupak prema zahtjevu 11 ili 12, pri čemu se spomenuta reakcija izvodi na temperaturi od oko 45 °C do 55 °C.
14. Postupak prema bilo kojem od zahtjeva 11-13, što postupak dalje obuhvaća:
dodavanje klorovodične kiseline spoju Formule I na sobnoj temperaturi da bi se oblikovala suspenzija; zagrijavanje spomenute suspenzije do temperature od oko 45 °C do 55 °C da bi se oblikovao rastvor; i hlađenje rastvora do temperature od oko 0 °C do 5 °C da bi spomenuta sol kristalizala.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562121697P | 2015-02-27 | 2015-02-27 | |
PCT/US2016/019741 WO2016138363A1 (en) | 2015-02-27 | 2016-02-26 | Salts of pi3k inhibitor and processes for their preparation |
EP16718921.6A EP3262046B1 (en) | 2015-02-27 | 2016-02-26 | Salts of pi3k inhibitor and processes for their preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210036T1 true HRP20210036T1 (hr) | 2021-03-05 |
Family
ID=55854770
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20221444TT HRP20221444T1 (hr) | 2015-02-27 | 2016-02-26 | Postupci za pripravu pi3k inhibitora |
HRP20210036TT HRP20210036T1 (hr) | 2015-02-27 | 2021-01-08 | Soli inhibitora pi3k i postupci za njihovo dobivanje |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20221444TT HRP20221444T1 (hr) | 2015-02-27 | 2016-02-26 | Postupci za pripravu pi3k inhibitora |
Country Status (37)
Country | Link |
---|---|
US (3) | US10336759B2 (hr) |
EP (3) | EP4183789A1 (hr) |
JP (2) | JP6816005B2 (hr) |
KR (1) | KR20170132185A (hr) |
CN (4) | CN107580597A (hr) |
AR (1) | AR103804A1 (hr) |
AU (3) | AU2016222556B2 (hr) |
BR (1) | BR122021004509B1 (hr) |
CA (1) | CA2977659A1 (hr) |
CL (2) | CL2017002179A1 (hr) |
CO (1) | CO2017008924A2 (hr) |
CR (2) | CR20170389A (hr) |
CY (1) | CY1123729T1 (hr) |
DK (2) | DK3262046T3 (hr) |
EA (1) | EA201791923A1 (hr) |
EC (2) | ECSP17064131A (hr) |
ES (2) | ES2843522T3 (hr) |
HK (1) | HK1248229A1 (hr) |
HR (2) | HRP20221444T1 (hr) |
HU (2) | HUE053025T2 (hr) |
IL (1) | IL254093B (hr) |
LT (2) | LT3831833T (hr) |
MA (2) | MA41607B1 (hr) |
MD (2) | MD3831833T2 (hr) |
MX (2) | MX2017010918A (hr) |
MY (1) | MY187502A (hr) |
NZ (2) | NZ773226A (hr) |
PE (2) | PE20180129A1 (hr) |
PH (2) | PH12017501538A1 (hr) |
PL (2) | PL3831833T3 (hr) |
PT (2) | PT3831833T (hr) |
RS (2) | RS63963B1 (hr) |
SG (3) | SG11201706917WA (hr) |
SI (2) | SI3262046T1 (hr) |
TW (2) | TWI748941B (hr) |
UA (1) | UA122332C2 (hr) |
WO (1) | WO2016138363A1 (hr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME01838B (me) | 2009-06-29 | 2014-12-20 | Lncyte Holdings Corp | Pirimidinoni kao inhibitori pi3k |
EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
MX2020004502A (es) | 2011-09-02 | 2022-01-20 | Incyte Holdings Corp | Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k). |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
TW202214254A (zh) * | 2013-03-01 | 2022-04-16 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
KR20230044320A (ko) | 2014-04-08 | 2023-04-03 | 인사이트 코포레이션 | Jak 및 pi3k 억제제 조합에 의한 b-세포 악성종양의 치료 |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
CR20170389A (es) | 2015-02-27 | 2018-01-26 | Incyte Corp | Sales de inhibidor de p13k y procesos de preparación |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
EP3360878B9 (en) | 2015-12-11 | 2021-05-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Azetidine derivative, preparation method therefor, and use thereof |
PT3762368T (pt) | 2018-03-08 | 2022-05-06 | Incyte Corp | Compostos de aminopirazina diol como inibidores de pi3k-y |
CA3101323A1 (en) | 2018-06-01 | 2019-12-05 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
EP4251138A1 (en) | 2020-11-30 | 2023-10-04 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
TW202329976A (zh) | 2021-12-16 | 2023-08-01 | 美商英塞特公司 | P13K—δ抑制劑之局部調配物 |
CN114409654A (zh) * | 2021-12-30 | 2022-04-29 | 安徽普利药业有限公司 | 一种btk抑制剂的中间体合成方法 |
Family Cites Families (281)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3169967A (en) | 1957-11-14 | 1965-02-16 | Ciba Geigy Corp | Methyl o-lower alkanoyl-reserpates |
US3037980A (en) | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
US3506643A (en) | 1966-12-09 | 1970-04-14 | Max Thiel | N**6-aralkyl-adenosine derivatives |
DE2139107A1 (de) | 1971-08-04 | 1973-02-15 | Merck Patent Gmbh | Heterocyclisch substituierte adenosinverbindungen |
US3962443A (en) | 1972-08-14 | 1976-06-08 | Dainippon Pharmaceutical Co., Ltd. | Antibacterial pharmaceutical compositions and processes for preparation thereof |
DE2248232A1 (de) | 1972-10-02 | 1974-04-11 | Basf Ag | 4-thiopyrimido eckige klammer auf 4,5-d eckige klammer zu pyrimidine |
AR204003A1 (es) | 1973-04-03 | 1975-11-12 | Dainippon Pharmaceutical Co | Procedimiento para preparar compuestos derivados del acido 2-(1-piperazinil)-5-oxopirido-(2,3-d)pirimidino-6-carboxilico y sus sales farmaceuticamente aceptables |
US3862189A (en) | 1973-08-14 | 1975-01-21 | Warner Lambert Co | Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents |
US3936454A (en) | 1973-08-14 | 1976-02-03 | Warner-Lambert Company | 5-Amino-4-chloro-6-(substituted amino)-pyrimidines |
DK3375A (hr) | 1974-01-25 | 1975-09-15 | Ciba Geigy Ag | |
JPS587626B2 (ja) | 1974-02-13 | 1983-02-10 | 大日本製薬株式会社 | ナフチリジン オヨビ キノリンユウドウタイノセイホウ |
JPS5359663A (en) | 1976-11-09 | 1978-05-29 | Sumitomo Chem Co Ltd | 2-halogeno methyl indole derivatives and process for praparation of the same |
JPS52106897A (en) | 1977-01-10 | 1977-09-07 | Dainippon Pharmaceut Co Ltd | Synthesis of piperazine derivatives |
JPS5392767A (en) | 1977-01-27 | 1978-08-15 | Sumitomo Chem Co Ltd | Preparation of 2-phthalimidomethylindole derivatives |
JPS5625234A (en) | 1979-08-02 | 1981-03-11 | Hitachi Denshi Ltd | Dropout display system |
JPS56123981A (en) | 1981-02-23 | 1981-09-29 | Dainippon Pharmaceut Co Ltd | Preparation of 1,4-disubstituted piperazine |
JPS5883698A (ja) | 1981-11-13 | 1983-05-19 | Takeda Chem Ind Ltd | キノン化合物およびその製造法 |
JPS58162949A (ja) | 1982-03-20 | 1983-09-27 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀カラ−写真感光材料 |
JPS60140373U (ja) | 1984-02-28 | 1985-09-17 | 東洋ハ−ネス株式会社 | ワイヤハ−ネスのア−ス構造 |
JPS6190153A (ja) | 1984-10-09 | 1986-05-08 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
JPS62103640A (ja) | 1985-07-18 | 1987-05-14 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料 |
JPH07119970B2 (ja) | 1986-04-18 | 1995-12-20 | 富士写真フイルム株式会社 | 画像形成方法 |
JPS6310746A (ja) | 1986-07-01 | 1988-01-18 | Tanabe Seiyaku Co Ltd | ナフタレン誘導体 |
CA1324609C (en) | 1986-07-30 | 1993-11-23 | Eastman Kodak Company | Photographic element and process |
US4861701A (en) | 1987-10-05 | 1989-08-29 | Eastman Kodak Company | Photographic element and process comprising a compound which comprises two timing groups in sequence |
AT388372B (de) | 1987-10-08 | 1989-06-12 | Tanabe Seiyaku Co | Neue naphthalinderivate und sie enthaltende pharmazeutika |
JPH01250316A (ja) | 1987-12-28 | 1989-10-05 | Tanabe Seiyaku Co Ltd | 抗脂血剤 |
EP0364598A4 (en) | 1988-03-02 | 1992-01-15 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof |
US5208250A (en) | 1988-05-25 | 1993-05-04 | Warner-Lambert Company | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents |
RU2054004C1 (ru) | 1990-04-25 | 1996-02-10 | Ниссан Кемикал Индастриз Лтд. | Производные 3(2н)-пиридазинона или их фармацевтически приемлемые соли и фармацевтическая композиция на их основе |
SU1712359A1 (ru) | 1990-05-07 | 1992-02-15 | Уфимский Нефтяной Институт | Гидрохлорид 8 @ -гидроксихинолинового эфира 8-гидроксихинолин-7-карбоновой кислоты, в качестве бактерицида дл подавлени сульфатвосстанавливающих бактерий и культур РSеUDомоNаS и АRтнRовастеR |
DE69129389T2 (de) | 1990-06-28 | 1998-10-08 | Fuji Photo Film Co Ltd | Photographische Silberhalogenidmaterialien |
EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
JPH04190232A (ja) | 1990-11-26 | 1992-07-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
IL101860A0 (en) | 1991-05-31 | 1992-12-30 | Ici Plc | Heterocyclic derivatives |
JP3108483B2 (ja) | 1991-09-30 | 2000-11-13 | 日清製粉株式会社 | インドール誘導体およびこれを有効成分とする抗潰瘍薬 |
HUT64064A (en) | 1992-02-13 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing puyrido/1,2-a/pyrimidine derivatives and pharmaceutical compositions comprising same as active ingredient |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
AU3933493A (en) | 1992-04-24 | 1993-11-29 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal aminopyrimidines |
TW229140B (hr) | 1992-06-05 | 1994-09-01 | Shell Internat Res Schappej B V | |
FR2714907B1 (fr) | 1994-01-07 | 1996-03-29 | Union Pharma Scient Appl | Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant. |
US6342501B1 (en) | 1994-02-25 | 2002-01-29 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d] pyrimidines as antiviral agents |
JPH0987282A (ja) | 1995-09-21 | 1997-03-31 | Kyowa Hakko Kogyo Co Ltd | チアゾール誘導体 |
JPH09176162A (ja) | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
JPH09176116A (ja) | 1995-12-27 | 1997-07-08 | Toray Ind Inc | 複素環誘導体およびその医薬用途 |
JPH1025294A (ja) | 1996-03-26 | 1998-01-27 | Akira Matsuda | 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤 |
CA2258728C (en) | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
EP0882727B9 (en) | 1996-07-03 | 2005-06-15 | Sumitomo Pharmaceuticals Company, Limited | Novel purine derivatives |
US5866702A (en) | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
US6630496B1 (en) | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
JPH10231297A (ja) | 1997-02-20 | 1998-09-02 | Japan Energy Corp | 新規なアデニン−1−n−オキシド誘導体およびその医薬用途 |
WO1999024432A1 (en) | 1997-11-12 | 1999-05-20 | Mitsubishi Chemical Corporation | Purine derivatives and medicine containing the same as the active ingredient |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
HUP0100156A3 (en) | 1998-02-25 | 2002-12-28 | Genetics Inst Inc Cambridge | Indole derivatives as inhibitors of phospholipase a2 and use of them for producing pharmaceutical compositions |
BR9908280A (pt) | 1998-02-25 | 2000-10-31 | Genetics Inst | Inibidores de enzimas de fosfolipase |
US6828344B1 (en) | 1998-02-25 | 2004-12-07 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
ES2190221T3 (es) | 1998-05-04 | 2003-07-16 | Zentaris Ag | Derivados de indol y su uso para el tratamiento de enfermedades malignas y otras, que se basan en proliferaciones celulares patologicas. |
JP4549534B2 (ja) | 1998-05-26 | 2010-09-22 | 中外製薬株式会社 | 複素環を有するインドール誘導体及びモノ又はジアザインドール誘導体 |
JP3997651B2 (ja) | 1998-06-24 | 2007-10-24 | コニカミノルタホールディングス株式会社 | 新規色素及び画像記録材料及び感熱転写材料及びインクジェット記録液 |
CN1152031C (zh) | 1998-08-11 | 2004-06-02 | 诺瓦提斯公司 | 具有血管生成抑制活性的异喹啉衍生物 |
JP2002523412A (ja) | 1998-08-25 | 2002-07-30 | ザ ユーエイビー リサーチ ファウンデイション | 細菌nadシンテターゼ阻害剤 |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
DE60023268T2 (de) | 1999-02-01 | 2006-06-01 | CV Therapeutics, Inc., Palo Alto | INHIBITEURS PURIQUES DE KINASE 2 DEPENDANTE DES CYCLINES et IkB-alpha |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
JP2000281654A (ja) | 1999-03-26 | 2000-10-10 | Tanabe Seiyaku Co Ltd | イソキノリン誘導体 |
DE19932571A1 (de) | 1999-07-13 | 2001-01-18 | Clariant Gmbh | Verfahren zur Herstellung von Biarylen unter Palladophosphacyclobutan-Katalyse |
JP2001151771A (ja) | 1999-09-10 | 2001-06-05 | Kyowa Hakko Kogyo Co Ltd | 含窒素芳香族複素環誘導体 |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
EP1138328A1 (en) | 2000-03-29 | 2001-10-04 | Eli Lilly And Company Limited | Naphthalene derivatives as CNS drugs |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
CA2413330A1 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
CN1331340A (zh) | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人拓扑异构酶12.1和编码这种多肽的多核苷酸 |
EP1300398B1 (en) | 2000-07-05 | 2006-04-05 | Astellas Pharma Inc. | Propane-1,3-dione derivatives |
FR2814073B1 (fr) | 2000-09-21 | 2005-06-24 | Yang Ji Chemical Company Ltd | Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux derives de l'indole a titre de principes actifs d'une telle composition |
DOP2002000334A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz |
SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
US7148237B2 (en) | 2001-03-01 | 2006-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity |
UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
WO2002078700A1 (en) | 2001-03-30 | 2002-10-10 | Smithkline Beecham Corporation | Pyralopyridines, process for their preparation and use as therapteutic compounds |
US20050107400A1 (en) | 2001-03-30 | 2005-05-19 | Boyd Leslie F. | Use of pyrazolopyridines as therapeutic compounds |
ES2242028T3 (es) | 2001-04-27 | 2005-11-01 | Smithkline Beecham Corporation | Derivados de pirazolo(1,5-a)piridina. |
CZ294535B6 (cs) | 2001-08-02 | 2005-01-12 | Ústav Experimentální Botaniky Avčr | Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující |
GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
US8124625B2 (en) | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
MXPA04002035A (es) | 2001-09-26 | 2004-06-07 | Bayer Pharmaceuticals Corp | Derivados de 1, 8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados. |
EP1432714B1 (en) | 2001-10-02 | 2008-08-06 | Smithkline Beecham Corporation | Chemical compounds |
CA2462657C (en) | 2001-10-30 | 2011-04-26 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
US7262164B2 (en) | 2001-11-09 | 2007-08-28 | Enzon, Inc. | Polymeric thiol-linked prodrugs employing benzyl elimination systems |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
DE60222302T2 (de) | 2001-12-06 | 2008-05-29 | Merck & Co., Inc. | Inhibitoren von mitotischem kinesin |
AU2002357043B2 (en) | 2001-12-06 | 2008-04-24 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
TW200301135A (en) | 2001-12-27 | 2003-07-01 | Otsuka Maryland Res Inst Inc | Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
EP1484320A1 (en) | 2002-02-13 | 2004-12-08 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
WO2003074497A1 (en) | 2002-03-01 | 2003-09-12 | Pintex Pharmaceutical, Inc. | Pin1-modulating compounds and methods of use thereof |
WO2003084959A1 (en) | 2002-04-03 | 2003-10-16 | Bristol-Myers Squibb Company | Thiopene-based tricyclic compounds and pharmaceutical compositions comprising same |
US20040063658A1 (en) | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
AU2003257822A1 (en) | 2002-08-13 | 2004-04-30 | Shionogi And Co., Ltd. | Heterocyclic compound having hiv integrase inhibitory activity |
JP4190232B2 (ja) | 2002-08-26 | 2008-12-03 | 富士通株式会社 | 機械研磨を行う方法 |
ES2387388T3 (es) | 2002-09-27 | 2012-09-21 | Dainippon Sumitomo Pharma Co., Ltd. | Compuesto de adenina y uso del mismo |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
DK2316831T3 (da) | 2002-11-21 | 2013-06-10 | Novartis Ag | 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer |
CA2507509A1 (en) | 2002-11-25 | 2004-06-10 | Mochida Pharmaceutical Co., Ltd. | Therapeutic agent for respiratory disease containing 4-hydroxypiperidine derivative as active ingredient |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1577288B1 (en) | 2002-12-26 | 2014-07-23 | Eisai R&D Management Co., Ltd. | Selective estrogen receptor modulators |
CZ294538B6 (cs) | 2002-12-30 | 2005-01-12 | Ústav Experimentální Botaniky Akademie Vědčeské Re | Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující |
RU2233842C1 (ru) | 2003-01-13 | 2004-08-10 | Петров Владимир Иванович | Производные пурина, обладающие противовирусной активностью |
PE20050068A1 (es) | 2003-02-06 | 2005-03-11 | Novartis Ag | 2-cianopirrolopirimidinas como inhibidores de la catepsina s |
GB0304640D0 (en) | 2003-02-28 | 2003-04-02 | Novartis Ag | Organic compounds |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
SE0300908D0 (sv) | 2003-03-31 | 2003-03-31 | Astrazeneca Ab | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them |
US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
EP1619948A4 (en) | 2003-05-05 | 2007-02-14 | Neurogen Corp | SUBSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS |
ATE458735T1 (de) | 2003-06-20 | 2010-03-15 | Novartis Vaccines & Diagnostic | Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
JP4570015B2 (ja) | 2003-07-14 | 2010-10-27 | クミアイ化学工業株式会社 | 2−イソオキサゾリン誘導体及びそれを有効成分として含有する除草剤 |
WO2005016528A2 (en) | 2003-08-15 | 2005-02-24 | Irm Llc | 6-substituted anilino purines as rtk inhibitors |
CN101906106A (zh) | 2003-09-18 | 2010-12-08 | 康福玛医药公司 | 作为hsp90-抑制剂的新的杂环化合物 |
WO2005046578A2 (en) | 2003-09-23 | 2005-05-26 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
WO2005074603A2 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
WO2005077948A1 (ja) | 2004-02-16 | 2005-08-25 | Daiichi Pharmaceutical Co., Ltd. | 抗真菌作用複素環化合物 |
WO2005091857A2 (en) | 2004-03-12 | 2005-10-06 | Bayer Pharmaceuticals Corporation | 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders |
CN1560035A (zh) | 2004-03-12 | 2005-01-05 | 沈阳药科大学 | 5-羟基吲哚-3-羧酸脂类衍生物 |
US20070225303A1 (en) | 2004-03-26 | 2007-09-27 | Haruhisa Ogita | 8-Oxoadenine Compound |
US7217702B2 (en) | 2004-04-02 | 2007-05-15 | Adenosine Therapeutics, Llc | Selective antagonists of A2A adenosine receptors |
AU2005245875C1 (en) | 2004-05-13 | 2017-08-31 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
CA2566158A1 (en) | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
CN101023082A (zh) | 2004-07-22 | 2007-08-22 | 阿斯利康(瑞典)有限公司 | 用于治疗和预防癌症的稠合嘧啶酮类 |
DE102004044221A1 (de) | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
JP2008517057A (ja) | 2004-10-19 | 2008-05-22 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | インドールおよびベンゾイミダゾール誘導体 |
EP1807417A2 (en) | 2004-11-04 | 2007-07-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
JP2008520744A (ja) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
CN101106983A (zh) | 2004-11-24 | 2008-01-16 | 诺瓦提斯公司 | JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合 |
EP1885356A2 (en) | 2005-02-17 | 2008-02-13 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
WO2007002701A2 (en) | 2005-06-27 | 2007-01-04 | Amgen Inc. | Anti-inflammatory aryl nitrile compounds |
FR2889192A1 (fr) | 2005-07-27 | 2007-02-02 | Cytomics Systems Sa | Composes antifongiques, compositions contenant ces composes et leurs utilisations |
CA2619881A1 (en) | 2005-08-16 | 2007-02-22 | Genzyme Corporation | Chemokine receptor binding compounds |
US7642270B2 (en) | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
JPWO2007034817A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
NZ592990A (en) | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
EP1783114A1 (en) | 2005-11-03 | 2007-05-09 | Novartis AG | N-(hetero)aryl indole derivatives as pesticides |
WO2007059108A2 (en) | 2005-11-10 | 2007-05-24 | Chemocentryx, Inc. | Substituted quinolones and methods of use |
EP2348023B9 (en) | 2005-12-13 | 2017-03-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
US20100227880A1 (en) | 2006-01-25 | 2010-09-09 | Kristjan Gudmundsson | Chemical compounds |
UY30118A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compueto amina trisustituido |
PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
WO2007102392A1 (ja) | 2006-03-03 | 2007-09-13 | Shionogi & Co., Ltd. | Mmp-13選択的阻害剤 |
US20100273776A1 (en) | 2006-03-29 | 2010-10-28 | FOLDRx PHARMACEUTICALS, INC | Inhibition of alpha-synuclein toxicity |
AU2007347115A1 (en) | 2006-04-04 | 2008-10-23 | The Regents Of The University Of California | PI3 kinase antagonists |
WO2008002490A2 (en) | 2006-06-23 | 2008-01-03 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
US20080004253A1 (en) | 2006-06-30 | 2008-01-03 | Bryan James Branstetter | Thiazolopyrimidine modulators of TRPV1 |
US20080009508A1 (en) | 2006-07-10 | 2008-01-10 | Lucie Szucova | 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin |
EP2046788A1 (en) | 2006-07-12 | 2009-04-15 | Syngeta Participations AG | Triazolopyridine derivatives as herbicides |
HUE035116T2 (hu) | 2006-08-08 | 2018-05-02 | Chugai Pharmaceutical Co Ltd | PI3K inhibitor pirimidinszármazékok és alkalmazásuk |
US8883820B2 (en) | 2006-08-30 | 2014-11-11 | Cellzome Ltd. | Triazole derivatives as kinase inhibitors |
WO2008032033A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
EP1972631A1 (en) | 2007-03-23 | 2008-09-24 | Novartis AG | Imidazopyridazines as PI3K lipid kinase inhibitors |
US20080114007A1 (en) | 2006-10-31 | 2008-05-15 | Player Mark R | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase |
JP5313909B2 (ja) | 2006-11-13 | 2013-10-09 | アイコス コーポレイション | 炎症性疾患および癌の処置のためのチエノピリミジノン |
SI3034075T1 (sl) | 2006-11-22 | 2018-12-31 | Incyte Holdings Corporation | Imidazotriazini in imidazopirimidini kot inhibitorji kinaze |
CA2672960A1 (en) | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
WO2008080844A1 (en) | 2006-12-29 | 2008-07-10 | F. Hoffmann-La Roche Ag | Azaspiro derivatives |
CL2008000369A1 (es) | 2007-02-05 | 2008-04-18 | Xenon Pharmaceuticals Inc | Compuestos derivados de piridopirimidinonas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dolor, depresion, enfermedades cardiovasculares, enfermedades respiratorias y enfermedades psiquiatricas. |
CA2676906A1 (en) | 2007-02-12 | 2008-08-21 | Intermune, Inc. | Novel inhibitors hepatitis c virus replication |
PE20081887A1 (es) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Nuevo compuesto de adenina |
US20080233127A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
CA2680783C (en) | 2007-03-23 | 2012-04-24 | Amgen Inc. | Heterocyclic compounds and their uses |
RS54706B1 (en) | 2007-03-23 | 2016-08-31 | Amgen Inc. | HETEROCYCLIC UNITS AND THEIR USES |
US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
AU2008266856A1 (en) | 2007-06-18 | 2008-12-24 | University Of Louisville Research Foundation, Inc. | Family of PFKFB3 inhibitors with anti-neoplastic activities |
NZ582090A (en) | 2007-06-29 | 2012-05-25 | Gilead Sciences Inc | Purine derivatives and their use as modulators of toll-like receptor 7 |
WO2009042294A2 (en) | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
JP2009076865A (ja) | 2007-08-29 | 2009-04-09 | Fujifilm Corp | 有機電界発光素子 |
TW200916447A (en) | 2007-08-29 | 2009-04-16 | Methylgene Inc | Sirtuin inhibitors |
WO2009034386A1 (en) | 2007-09-13 | 2009-03-19 | Astrazeneca Ab | Derivatives of adenine and 8-aza-adenine and uses thereof-796 |
JP2009080233A (ja) | 2007-09-26 | 2009-04-16 | Kyocera Mita Corp | 電子写真感光体 |
CZ300774B6 (cs) | 2007-10-05 | 2009-08-05 | Univerzita Palackého | Substituované 6-(alkylbenzylamino)purinové deriváty pro použití jako antagonisté cytokininových receptoru a prípravky obsahující tyto slouceniny |
BRPI0820342A2 (pt) | 2007-11-07 | 2015-05-26 | Foldrx Pharmaceuticals Inc | Modulação de tráfego de proteína |
WO2009063235A1 (en) | 2007-11-13 | 2009-05-22 | Astrazeneca Ab | Derivatives of 1,9-dihydro-6h-purin-6-one and uses thereof-018 |
JP2009120686A (ja) | 2007-11-14 | 2009-06-04 | Toyo Ink Mfg Co Ltd | 光重合開始剤、重合性組成物、および重合物の製造方法。 |
PE20091268A1 (es) | 2007-12-19 | 2009-09-19 | Amgen Inc | Derivados heterociclicos como inhibidores de pi3 quinasa |
WO2009081105A2 (en) | 2007-12-21 | 2009-07-02 | Ucb Pharma S.A. | Quinoxaline and quinoline derivatives as kinase inhibitors |
AU2008345681A1 (en) | 2007-12-21 | 2009-07-09 | Wyeth Llc | Imidazo [1,2-a] pyridine compounds |
US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
US7960397B2 (en) | 2007-12-28 | 2011-06-14 | Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic | 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions |
WO2009082845A1 (en) | 2007-12-28 | 2009-07-09 | Topharman Shanghai Co., Ltd. | N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)benzenesulfonyl)-4,5-dihydro-5-oxo-1,2,4-triazin-6-yl]ethyl}butyramide, the preparation method and use thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
NZ586642A (en) | 2008-01-11 | 2012-04-27 | Natco Pharma Ltd | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents |
US9089572B2 (en) | 2008-01-17 | 2015-07-28 | California Institute Of Technology | Inhibitors of p97 |
CN101981037B (zh) | 2008-01-30 | 2013-09-04 | 吉宁特有限公司 | 吡唑并嘧啶pi3k抑制剂化合物及使用方法 |
EP2444403A1 (en) | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Heterocyclic compound having inhibitory activity on PI3K |
US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
WO2009140215A2 (en) | 2008-05-11 | 2009-11-19 | Geraghty, Erin | Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds |
US10301265B2 (en) | 2008-05-28 | 2019-05-28 | Virginia I. Roxas-Duncan | Small molecule inhibitors of botulinum neurotoxins |
CA2727174A1 (en) | 2008-06-20 | 2010-01-21 | Jiangao Song | Aryl gpr119 agonists and uses thereof |
US8026271B2 (en) | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
WO2010018458A2 (en) | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Phenol derivatives and methods of use thereof |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
CN102271683B (zh) | 2008-11-13 | 2014-07-09 | 吉里德卡利斯托加公司 | 恶性血液病的治疗 |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
BR122013027950A2 (pt) | 2008-12-24 | 2019-12-10 | BIAL PORTELA & Cª S A | compostos farmacêuticos |
WO2010083444A1 (en) | 2009-01-15 | 2010-07-22 | Anvyl, Llc | Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
EP2396315B1 (en) | 2009-02-13 | 2016-08-31 | UCB Biopharma SPRL | Quinoline derivatives as pi3k kinase inhibitors |
TW201100428A (en) | 2009-03-31 | 2011-01-01 | Arqule Inc | Substituted indolo-piperidine compounds |
WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
EP2421536B1 (en) | 2009-04-20 | 2015-08-26 | Gilead Calistoga LLC | Methods of treatment for solid tumors |
WO2010127208A1 (en) | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
CN102458581B (zh) | 2009-05-22 | 2016-03-30 | 因塞特控股公司 | 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物 |
EA201270013A1 (ru) | 2009-06-25 | 2012-06-29 | Амген Инк. | Гетероциклические соединения и их применение |
JP2012531435A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | PI3K阻害剤としての4H−ピリド[1,2−a]ピリミジン−4−オン誘導体 |
EP2448582B1 (en) | 2009-06-29 | 2017-04-19 | Agios Pharmaceuticals, Inc. | Quinoline-8-sulfonamide derivatives having an anticancer activity |
ME01838B (me) | 2009-06-29 | 2014-12-20 | Lncyte Holdings Corp | Pirimidinoni kao inhibitori pi3k |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
WO2011011550A1 (en) | 2009-07-21 | 2011-01-27 | Calistoga Pharmaceuticals Inc. | Treatment of liver disorders with pi3k inhibitors |
WO2011025889A1 (en) | 2009-08-28 | 2011-03-03 | Takeda Pharmaceutical Company Limited | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
EP2491039A1 (en) | 2009-10-20 | 2012-08-29 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
US8962652B2 (en) | 2009-10-22 | 2015-02-24 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
AU2010316780B2 (en) | 2009-11-05 | 2015-07-16 | Rhizen Pharmaceuticals Sa | Novel benzopyran kinase modulators |
GEP20146169B (en) | 2009-11-10 | 2014-09-25 | Pfizer | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
ES2534096T3 (es) | 2009-11-12 | 2015-04-17 | Ucb Pharma, S.A. | Derivados de piridina y pirazina bicíclicos condensados como inhibidores de quinasa |
WO2011058111A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Aminopurine derivatives as kinase inhibitors |
US10174033B2 (en) | 2009-12-10 | 2019-01-08 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof |
US8680108B2 (en) | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
WO2011075628A1 (en) | 2009-12-18 | 2011-06-23 | Amgen Inc. | Heterocyclic compounds and their uses |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
JP2011136925A (ja) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
US8921382B2 (en) | 2010-01-07 | 2014-12-30 | Dow Agrosciences, Llc. | Thiazolo[5,4-d] pyrimidines and their use as agrochemicals |
US8633183B2 (en) | 2010-01-26 | 2014-01-21 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
ME02386B (me) | 2010-03-10 | 2016-09-20 | Incyte Holdings Corp | Derivati piperidin-4-il azetidina kao inhibitori jak1 |
KR20130028081A (ko) | 2010-03-22 | 2013-03-18 | 그렌마크 파머수티칼스 에스. 아. | 피리미딘온 유도체를 포함하는 약제학적 조성물 |
UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
CN103002738A (zh) | 2010-05-21 | 2013-03-27 | 英特利凯恩有限责任公司 | 用于激酶调节的化学化合物、组合物和方法 |
CA2802484A1 (en) | 2010-06-11 | 2011-12-15 | Gilead Calistoga Llc | Methods of treating hematological disorders with quinazolinone compounds in selected patients |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
WO2012003274A1 (en) | 2010-07-01 | 2012-01-05 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
CA2803259A1 (en) | 2010-07-01 | 2012-01-05 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
AU2011272850A1 (en) | 2010-07-02 | 2013-01-10 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of PI3K activity |
WO2012040634A1 (en) | 2010-09-24 | 2012-03-29 | Gilead Calistoga Llc | Atropisomers of pi3k-inhibiting compounds |
EP2635565A1 (en) | 2010-11-04 | 2013-09-11 | Amgen Inc. | 5 -cyano-4, 6 -diaminopyrimidine or 6 -aminopurine derivatives as pi3k- delta inhibitors |
CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
US8765768B2 (en) | 2010-11-17 | 2014-07-01 | Amgen Inc. | Heterocyclic compounds and their uses |
EP2640723A1 (en) | 2010-11-19 | 2013-09-25 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
US20140031547A1 (en) | 2010-12-14 | 2014-01-30 | Electrophoretics Limited | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES |
EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
EP2655342A1 (en) | 2010-12-23 | 2013-10-30 | Amgen Inc. | Heterocyclic compounds and their uses |
NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
USRE47009E1 (en) | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
MX2020004502A (es) | 2011-09-02 | 2022-01-20 | Incyte Holdings Corp | Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k). |
EP2763994A4 (en) | 2011-10-04 | 2015-08-26 | Gilead Calistoga Llc | NEW QUINOXALINE INHIBITORS OF THE PI3K PATH |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
PE20151141A1 (es) | 2012-11-01 | 2015-08-06 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de jak |
TW202214254A (zh) * | 2013-03-01 | 2022-04-16 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
CN105026400A (zh) * | 2013-03-15 | 2015-11-04 | 詹森药业有限公司 | 用于制备药物的方法和中间体 |
ME02763B (me) | 2013-05-17 | 2018-01-20 | Incyte Corp | Derivati bipirazola kao inhibitori jak |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
CR20170389A (es) | 2015-02-27 | 2018-01-26 | Incyte Corp | Sales de inhibidor de p13k y procesos de preparación |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2016183062A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
-
2016
- 2016-02-26 CR CR20170389A patent/CR20170389A/es unknown
- 2016-02-26 EP EP22202130.5A patent/EP4183789A1/en active Pending
- 2016-02-26 HU HUE16718921A patent/HUE053025T2/hu unknown
- 2016-02-26 RS RS20221159A patent/RS63963B1/sr unknown
- 2016-02-26 BR BR122021004509-7A patent/BR122021004509B1/pt active IP Right Grant
- 2016-02-26 DK DK16718921.6T patent/DK3262046T3/da active
- 2016-02-26 EP EP20201979.0A patent/EP3831833B1/en active Active
- 2016-02-26 CN CN201680011760.XA patent/CN107580597A/zh not_active Withdrawn
- 2016-02-26 HR HRP20221444TT patent/HRP20221444T1/hr unknown
- 2016-02-26 MD MDE20220030T patent/MD3831833T2/ro unknown
- 2016-02-26 ES ES16718921T patent/ES2843522T3/es active Active
- 2016-02-26 UA UAA201709412A patent/UA122332C2/uk unknown
- 2016-02-26 RS RS20201563A patent/RS61233B1/sr unknown
- 2016-02-26 CR CR20210055A patent/CR20210055A/es unknown
- 2016-02-26 WO PCT/US2016/019741 patent/WO2016138363A1/en active Application Filing
- 2016-02-26 SI SI201630994T patent/SI3262046T1/sl unknown
- 2016-02-26 DK DK20201979.0T patent/DK3831833T3/da active
- 2016-02-26 PT PT202019790T patent/PT3831833T/pt unknown
- 2016-02-26 TW TW105106000A patent/TWI748941B/zh active
- 2016-02-26 PL PL20201979.0T patent/PL3831833T3/pl unknown
- 2016-02-26 LT LTEP20201979.0T patent/LT3831833T/lt unknown
- 2016-02-26 SG SG11201706917WA patent/SG11201706917WA/en unknown
- 2016-02-26 EP EP16718921.6A patent/EP3262046B1/en active Active
- 2016-02-26 HU HUE20201979A patent/HUE060953T2/hu unknown
- 2016-02-26 EA EA201791923A patent/EA201791923A1/ru unknown
- 2016-02-26 SG SG10201907576SA patent/SG10201907576SA/en unknown
- 2016-02-26 CN CN202311539089.4A patent/CN117800973A/zh active Pending
- 2016-02-26 US US15/054,474 patent/US10336759B2/en active Active
- 2016-02-26 MA MA41607A patent/MA41607B1/fr unknown
- 2016-02-26 PE PE2017001461A patent/PE20180129A1/es unknown
- 2016-02-26 PL PL16718921T patent/PL3262046T3/pl unknown
- 2016-02-26 AR ARP160100515A patent/AR103804A1/es unknown
- 2016-02-26 JP JP2017544953A patent/JP6816005B2/ja active Active
- 2016-02-26 TW TW109141640A patent/TWI764392B/zh active
- 2016-02-26 NZ NZ773226A patent/NZ773226A/en unknown
- 2016-02-26 CN CN202311519531.7A patent/CN117777139A/zh active Pending
- 2016-02-26 PE PE2022000834A patent/PE20230156A1/es unknown
- 2016-02-26 AU AU2016222556A patent/AU2016222556B2/en active Active
- 2016-02-26 SI SI201631644T patent/SI3831833T1/sl unknown
- 2016-02-26 KR KR1020177027583A patent/KR20170132185A/ko not_active Application Discontinuation
- 2016-02-26 MA MA55193A patent/MA55193B1/fr unknown
- 2016-02-26 SG SG10201912302VA patent/SG10201912302VA/en unknown
- 2016-02-26 LT LTEP16718921.6T patent/LT3262046T/lt unknown
- 2016-02-26 CA CA2977659A patent/CA2977659A1/en active Pending
- 2016-02-26 MY MYPI2017001264A patent/MY187502A/en unknown
- 2016-02-26 PT PT167189216T patent/PT3262046T/pt unknown
- 2016-02-26 MX MX2017010918A patent/MX2017010918A/es active IP Right Grant
- 2016-02-26 MD MDE20180031T patent/MD3262046T2/ro unknown
- 2016-02-26 CN CN202311505572.0A patent/CN117736209A/zh active Pending
- 2016-02-26 ES ES20201979T patent/ES2933694T3/es active Active
- 2016-02-26 NZ NZ734993A patent/NZ734993A/en unknown
-
2017
- 2017-08-22 IL IL254093A patent/IL254093B/en unknown
- 2017-08-24 MX MX2019012927A patent/MX2019012927A/es unknown
- 2017-08-25 CL CL2017002179A patent/CL2017002179A1/es unknown
- 2017-08-25 PH PH12017501538A patent/PH12017501538A1/en unknown
- 2017-08-30 CO CONC2017/0008924A patent/CO2017008924A2/es unknown
- 2017-09-26 EC ECIEPI201764131A patent/ECSP17064131A/es unknown
-
2018
- 2018-06-14 HK HK18107731.9A patent/HK1248229A1/zh unknown
-
2019
- 2019-06-21 US US16/448,815 patent/US11084822B2/en active Active
- 2019-11-07 CL CL2019003188A patent/CL2019003188A1/es unknown
-
2020
- 2020-05-07 PH PH12020550575A patent/PH12020550575A1/en unknown
- 2020-08-11 AU AU2020217339A patent/AU2020217339B2/en active Active
- 2020-09-09 JP JP2020151255A patent/JP7080941B2/ja active Active
-
2021
- 2021-01-08 HR HRP20210036TT patent/HRP20210036T1/hr unknown
- 2021-01-22 CY CY20211100051T patent/CY1123729T1/el unknown
- 2021-03-02 EC ECSENADI202114448A patent/ECSP21014448A/es unknown
- 2021-07-01 US US17/365,888 patent/US20220024934A1/en active Pending
- 2021-12-10 AU AU2021282550A patent/AU2021282550A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210036T1 (hr) | Soli inhibitora pi3k i postupci za njihovo dobivanje | |
CA3025806C (en) | Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use | |
HRP20201582T1 (hr) | Polimorf sik inhibitora | |
IL283943B2 (en) | Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders | |
CN102869359A (zh) | 咪唑并吡啶和嘌呤化合物、组合物和使用方法 | |
SI3087075T1 (en) | SYK INHIBITORS | |
NZ769326A (en) | Heterocyclylamines as pi3k inhibitors | |
WO2018046933A1 (en) | Tankyrase inhibitors | |
HRP20221221T1 (hr) | Pirimidinski spoj kao inhibitor jak kinaze | |
AU2012204982A1 (en) | 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors | |
CN102858754A (zh) | Raf抑制剂化合物及其使用方法 | |
AU2020249397A1 (en) | Bicyclic HPK1 inhibitors | |
Farag et al. | Reprofiling of pyrimidine-based DAPK1/CSF1R dual inhibitors: identification of 2, 5-diamino-4-pyrimidinol derivatives as novel potential anticancer lead compounds | |
TW202126643A (zh) | 雜環化合物 | |
WO2015069441A1 (en) | Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk) | |
WO2020010003A1 (en) | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS | |
Siddesh et al. | Synthesis of thiophene-linked pyrimidopyrimidines as pharmaceutical leads | |
CA2862832A1 (en) | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof | |
CN104557871B (zh) | 具有螺环取代基的芳基吗啉类化合物,其制备方法和用途 | |
KR102124449B1 (ko) | 7H-피롤로[2,3-d]피리미딘 화합물을 제조하기 위한 방법 | |
CN103827115A (zh) | 咪唑并吡啶化合物、组合物和使用方法 | |
AU2020386189A1 (en) | Adenosine receptor antagonist compounds | |
CA3159211A1 (en) | Fluorinated quinoline, quinoxaline and benzo[b][1,4]oxazine derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors for the treatment of cancer, autoimmune and inflammatory diseases | |
CN110938071A (zh) | 一类具有激酶抑制活性的芳香杂环类化合物 | |
KR20210091121A (ko) | 포스포이노시티드 3-키나아제 (pi3k) 억제제의 결정질 형태 |